risperidone has been researched along with Genetic Predisposition in 30 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified novel candidate genes for treatment response to risperidone and provide evidence that one of these additionally may confer susceptibility to schizophrenia." | 9.14 | Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. ( Arinami, T; Hashimoto, R; Honda, H; Ikeda, M; Iwata, N; Kinoshita, Y; Koga, M; Mouri, A; Nabeshima, T; Nakamura, J; O'Donovan, MC; Okochi, T; Owen, MJ; Ozaki, N; Takeda, M; Tomita, Y; Williams, HJ; Yamanouchi, Y; Yoshimura, R, 2010) |
| " In this study we evaluated the role of six polymorphisms of the DRD2 gene in 125 risperidone-treated Chinese schizophrenia patients following the hypothesis that variation in the DRD2 gene could affect drug response." | 9.12 | The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. ( Duan, S; Feng, G; Gao, J; Gao, R; He, L; Li, H; Meng, J; Qian, X; Qin, W; Wong, S; Wu, S; Xing, Q; Xu, M, 2007) |
| "The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients." | 7.88 | UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Pasomsub, E; Puangpetch, A; Sukasem, C; Suthisisang, C; Vanwong, N; Wilffert, B, 2018) |
| "In children and adolescents treated with risperidone, hyperprolactinemia is a frequent complication that may have clinical repercussions." | 7.81 | Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. ( Celeri, EH; Dalgalarrondo, P; de Mello, MP; Della Torre, OH; dos Santos Júnior, A; Ferreira Neto, AP; Fontana, TS; Guerra Júnior, G; Henriques, TB; Paes, LA; Sewaybricker, LE, 2015) |
| "The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia." | 7.80 | Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. ( Fan, X; Feng, Y; Gao, J; Li, X; Lv, L; Nemani, K; Pang, L; Song, X; Zhang, H; Zhang, J; Zhang, W, 2014) |
| " We investigated the possible association of CYP2E1 polymorphisms with susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in schizophrenia patients." | 7.78 | Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. ( Feng, G; Han, X; He, L; Huo, R; Niu, J; Qin, S; Shen, L; Tang, K; Tian, Z; Wei, Z; Wu, X; Xiong, Y; Yang, L, 2012) |
| "To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone." | 7.75 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009) |
| "The study recruited 107 drug-naive Chinese schizophrenia patients who were given 8 weeks of risperidone monotherapy and it explored three of four single nucleotide polymorphisms spanning HTR3A for possible association with therapeutic improvement, using the Positive and Negative Symptom Scale." | 7.74 | Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. ( Feng, GY; Gu, B; He, L; Li, HF; Ma, G; Wang, L; Xing, QH; Zhang, AP; Zhao, XZ, 2008) |
| "These findings suggest that RGS4 variances influence clinical manifestations of schizophrenia as well as the treatment response to risperidone, suggesting that RGS4 plays a role in the fundamental process of disease pathophysiology." | 7.74 | RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. ( Chang, YC; Huang, CH; Huang, CL; Lane, HY; Liu, YC; Tsai, GE; Wu, PL, 2008) |
| "We identified novel candidate genes for treatment response to risperidone and provide evidence that one of these additionally may confer susceptibility to schizophrenia." | 5.14 | Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. ( Arinami, T; Hashimoto, R; Honda, H; Ikeda, M; Iwata, N; Kinoshita, Y; Koga, M; Mouri, A; Nabeshima, T; Nakamura, J; O'Donovan, MC; Okochi, T; Owen, MJ; Ozaki, N; Takeda, M; Tomita, Y; Williams, HJ; Yamanouchi, Y; Yoshimura, R, 2010) |
| "Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine." | 5.12 | DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. ( Ekholm, J; Goldman, D; Gunduz-Bruce, H; Kane, JM; Lencz, T; Malhotra, AK; Robinson, DG; Sevy, S; Woerner, MG; Xu, K, 2006) |
| " In this study we evaluated the role of six polymorphisms of the DRD2 gene in 125 risperidone-treated Chinese schizophrenia patients following the hypothesis that variation in the DRD2 gene could affect drug response." | 5.12 | The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. ( Duan, S; Feng, G; Gao, J; Gao, R; He, L; Li, H; Meng, J; Qian, X; Qin, W; Wong, S; Wu, S; Xing, Q; Xu, M, 2007) |
| "The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients." | 3.88 | UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Pasomsub, E; Puangpetch, A; Sukasem, C; Suthisisang, C; Vanwong, N; Wilffert, B, 2018) |
| "In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone." | 3.88 | Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. ( Belangero, SI; Breen, G; Bressan, RA; Carvalho, CM; Cordeiro, Q; Curtis, C; de Jong, S; Gadelha, A; Gouvea, E; Lee, SH; Moretti, P; Newhouse, S; Noto, C; Ota, V; Patel, H; Santoro, ML; Spindola, LM; Talarico, F, 2018) |
| "In children and adolescents treated with risperidone, hyperprolactinemia is a frequent complication that may have clinical repercussions." | 3.81 | Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. ( Celeri, EH; Dalgalarrondo, P; de Mello, MP; Della Torre, OH; dos Santos Júnior, A; Ferreira Neto, AP; Fontana, TS; Guerra Júnior, G; Henriques, TB; Paes, LA; Sewaybricker, LE, 2015) |
| "The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia." | 3.80 | Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. ( Fan, X; Feng, Y; Gao, J; Li, X; Lv, L; Nemani, K; Pang, L; Song, X; Zhang, H; Zhang, J; Zhang, W, 2014) |
| " We investigated the possible association of CYP2E1 polymorphisms with susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in schizophrenia patients." | 3.78 | Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. ( Feng, G; Han, X; He, L; Huo, R; Niu, J; Qin, S; Shen, L; Tang, K; Tian, Z; Wei, Z; Wu, X; Xiong, Y; Yang, L, 2012) |
| "To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone." | 3.75 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009) |
| "The study recruited 107 drug-naive Chinese schizophrenia patients who were given 8 weeks of risperidone monotherapy and it explored three of four single nucleotide polymorphisms spanning HTR3A for possible association with therapeutic improvement, using the Positive and Negative Symptom Scale." | 3.74 | Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. ( Feng, GY; Gu, B; He, L; Li, HF; Ma, G; Wang, L; Xing, QH; Zhang, AP; Zhao, XZ, 2008) |
| "We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic patients treated with olanzapine or risperidone for up to 4 months." | 3.74 | The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. ( Bilusic, H; Bozina, N; Hotujac, L; Kuzman, MR; Medved, V; Sain, I, 2008) |
| " Under medication with clozapine he had experienced a single event of seizures which were due to hypocalcemia." | 3.74 | [22q11.2 deletion and schizophrenia in childhood and adolescence]. ( Briegel, W, 2007) |
| "These findings suggest that RGS4 variances influence clinical manifestations of schizophrenia as well as the treatment response to risperidone, suggesting that RGS4 plays a role in the fundamental process of disease pathophysiology." | 3.74 | RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. ( Chang, YC; Huang, CH; Huang, CL; Lane, HY; Liu, YC; Tsai, GE; Wu, PL, 2008) |
| " Generally, the antipsychotics significantly enhanced NRG1/ErbB signaling with increased expression of NRG1 and phosphorylation of ErbB4 and ErbB2 in the brain and myocardium, except that clozapine partly blocked the cardiac NRG1/ErbB2 activation, which could be associated with its more severe cardiac adverse actions." | 1.43 | Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect. ( Cai, H; Dang, R; Guo, Y; Jiang, P; Liang, D; Lv, C; Yang, R, 2016) |
| "Susceptibility for malignant hyperthermia was detected by a positive in vitro contracture test." | 1.31 | [Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy]. ( Grohmann, R; Pedrosa Gil, F; Rüther, E; Schneider, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 13 (43.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, Q | 1 |
| Li, Y | 1 |
| Li, M | 1 |
| Qin, S | 3 |
| Ning, A | 1 |
| Yuan, R | 1 |
| Fu, Y | 1 |
| Wang, D | 1 |
| Zhang, R | 1 |
| Zeng, D | 1 |
| Yu, W | 1 |
| Li, H | 3 |
| Yu, S | 1 |
| Hongkaew, Y | 1 |
| Medhasi, S | 1 |
| Pasomsub, E | 1 |
| Ngamsamut, N | 1 |
| Puangpetch, A | 1 |
| Vanwong, N | 1 |
| Chamnanphon, M | 1 |
| Limsila, P | 1 |
| Suthisisang, C | 1 |
| Wilffert, B | 1 |
| Sukasem, C | 1 |
| Yeung, RK | 1 |
| Xiang, ZH | 1 |
| Tsang, SY | 1 |
| Li, R | 1 |
| Ho, TYC | 1 |
| Li, Q | 1 |
| Hui, CK | 1 |
| Sham, PC | 1 |
| Qiao, MQ | 1 |
| Xue, H | 1 |
| Santoro, ML | 1 |
| Ota, V | 1 |
| de Jong, S | 1 |
| Noto, C | 1 |
| Spindola, LM | 1 |
| Talarico, F | 1 |
| Gouvea, E | 1 |
| Lee, SH | 1 |
| Moretti, P | 1 |
| Curtis, C | 1 |
| Patel, H | 1 |
| Newhouse, S | 1 |
| Carvalho, CM | 1 |
| Gadelha, A | 1 |
| Cordeiro, Q | 1 |
| Bressan, RA | 1 |
| Belangero, SI | 1 |
| Breen, G | 1 |
| Nurmi, EL | 1 |
| Spilman, SL | 1 |
| Whelan, F | 1 |
| Scahill, LL | 1 |
| Aman, MG | 1 |
| McDougle, CJ | 1 |
| Arnold, LE | 1 |
| Handen, B | 1 |
| Johnson, C | 1 |
| Sukhodolsky, DG | 1 |
| Posey, DJ | 1 |
| Lecavalier, L | 1 |
| Stigler, KA | 1 |
| Ritz, L | 1 |
| Tierney, E | 1 |
| Vitiello, B | 1 |
| McCracken, JT | 1 |
| Wang, S | 1 |
| Li, W | 1 |
| Zhang, H | 2 |
| Wang, X | 1 |
| Yang, G | 1 |
| Zhao, J | 1 |
| Yang, Y | 1 |
| Lv, L | 2 |
| Song, X | 1 |
| Pang, L | 1 |
| Feng, Y | 1 |
| Fan, X | 1 |
| Li, X | 1 |
| Zhang, W | 1 |
| Gao, J | 2 |
| Zhang, J | 2 |
| Nemani, K | 1 |
| Mas, S | 1 |
| Gassó, P | 1 |
| Boloc, D | 1 |
| Rodriguez, N | 1 |
| Mármol, F | 1 |
| Sánchez, J | 1 |
| Bernardo, M | 1 |
| Lafuente, A | 1 |
| dos Santos Júnior, A | 1 |
| Henriques, TB | 1 |
| de Mello, MP | 1 |
| Ferreira Neto, AP | 1 |
| Paes, LA | 1 |
| Della Torre, OH | 1 |
| Sewaybricker, LE | 1 |
| Fontana, TS | 1 |
| Celeri, EH | 1 |
| Guerra Júnior, G | 1 |
| Dalgalarrondo, P | 1 |
| Dang, R | 1 |
| Guo, Y | 1 |
| Cai, H | 1 |
| Yang, R | 1 |
| Liang, D | 1 |
| Lv, C | 1 |
| Jiang, P | 1 |
| Gu, B | 2 |
| Wang, L | 3 |
| Zhang, AP | 2 |
| Ma, G | 1 |
| Zhao, XZ | 2 |
| Li, HF | 1 |
| Feng, GY | 2 |
| He, L | 5 |
| Xing, QH | 2 |
| Kuzman, MR | 1 |
| Medved, V | 1 |
| Bozina, N | 1 |
| Hotujac, L | 1 |
| Sain, I | 1 |
| Bilusic, H | 1 |
| Wei, Z | 2 |
| Xuan, J | 1 |
| Che, R | 1 |
| Du, J | 2 |
| Xing, Y | 1 |
| Yang, L | 2 |
| Li, J | 1 |
| Feng, G | 3 |
| Xing, Q | 2 |
| Calarge, CA | 1 |
| Ellingrod, VL | 1 |
| Acion, L | 1 |
| Miller, DD | 1 |
| Moline, J | 1 |
| Tansey, MJ | 1 |
| Schlechte, JA | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 1 |
| de Leon, J | 1 |
| Blakemore, AF | 1 |
| Arranz, MJ | 1 |
| Ikeda, M | 1 |
| Tomita, Y | 1 |
| Mouri, A | 1 |
| Koga, M | 1 |
| Okochi, T | 1 |
| Yoshimura, R | 1 |
| Yamanouchi, Y | 1 |
| Kinoshita, Y | 1 |
| Hashimoto, R | 2 |
| Williams, HJ | 1 |
| Takeda, M | 1 |
| Nakamura, J | 1 |
| Nabeshima, T | 1 |
| Owen, MJ | 1 |
| O'Donovan, MC | 1 |
| Honda, H | 1 |
| Arinami, T | 1 |
| Ozaki, N | 2 |
| Iwata, N | 2 |
| Bai, YM | 1 |
| Chen, TT | 1 |
| Liou, YJ | 1 |
| Hong, CJ | 1 |
| Tsai, SJ | 1 |
| Budisteanu, M | 1 |
| Papuc, SM | 1 |
| Tutulan-Cunita, A | 1 |
| Budisteanu, B | 1 |
| Arghir, A | 1 |
| Huo, R | 1 |
| Tang, K | 1 |
| Shen, L | 1 |
| Xiong, Y | 1 |
| Wu, X | 1 |
| Niu, J | 1 |
| Han, X | 1 |
| Tian, Z | 1 |
| Theodoulou, G | 1 |
| Milner, G | 1 |
| Jumaian, A | 1 |
| Lencz, T | 1 |
| Robinson, DG | 1 |
| Xu, K | 1 |
| Ekholm, J | 1 |
| Sevy, S | 1 |
| Gunduz-Bruce, H | 1 |
| Woerner, MG | 1 |
| Kane, JM | 1 |
| Goldman, D | 1 |
| Malhotra, AK | 1 |
| Qian, X | 1 |
| Wong, S | 1 |
| Wu, S | 1 |
| Duan, S | 1 |
| Xu, M | 1 |
| Gao, R | 1 |
| Qin, W | 1 |
| Meng, J | 1 |
| Yu, L | 1 |
| He, G | 1 |
| Tang, RQ | 1 |
| Ma, J | 1 |
| Xuan, JK | 1 |
| Xiao, Y | 1 |
| Gu, NF | 1 |
| Xu, MQ | 1 |
| Hashimoto, H | 1 |
| Shintani, N | 1 |
| Chiba, S | 1 |
| Hattori, S | 1 |
| Okada, T | 1 |
| Nakajima, M | 1 |
| Tanaka, K | 1 |
| Kawagishi, N | 1 |
| Nemoto, K | 1 |
| Mori, T | 1 |
| Ohnishi, T | 1 |
| Noguchi, H | 1 |
| Hori, H | 1 |
| Suzuki, T | 1 |
| Nakabayashi, T | 1 |
| Saitoh, O | 1 |
| Kosuga, A | 1 |
| Tatsumi, M | 1 |
| Kamijima, K | 1 |
| Weinberger, DR | 1 |
| Kunugi, H | 1 |
| Baba, A | 1 |
| Peñas-Lledó, EM | 1 |
| Dorado, P | 1 |
| Cáceres, MC | 1 |
| de la Rubia, A | 1 |
| Llerena, A | 1 |
| Marchesi, C | 1 |
| Tonna, M | 1 |
| Maggini, C | 1 |
| Briegel, W | 1 |
| Lane, HY | 1 |
| Liu, YC | 1 |
| Huang, CL | 1 |
| Chang, YC | 1 |
| Wu, PL | 1 |
| Huang, CH | 1 |
| Tsai, GE | 1 |
| Tsuang, MT | 1 |
| Stone, WS | 1 |
| Seidman, LJ | 1 |
| Faraone, SV | 1 |
| Zimmet, S | 1 |
| Wojcik, J | 1 |
| Kelleher, JP | 1 |
| Green, AI | 1 |
| Pedrosa Gil, F | 1 |
| Schneider, C | 1 |
| Grohmann, R | 1 |
| Rüther, E | 1 |
5 trials available for risperidone and Genetic Predisposition
| Article | Year |
|---|---|
Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; China; Female; Gene Frequency; Genetic Predisposition to Disease; Genom | 2009 |
Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
Topics: Animals; Antipsychotic Agents; Case-Control Studies; Databases, Genetic; Gene Frequency; Genetic Pre | 2010 |
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Genetic Predisposition to Disease; | 2006 |
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; Brief Psychiatric Rating Scale; Chi-Square Distribution; | 2007 |
Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies.
Topics: Adult; Antipsychotic Agents; Attention; Behavioral Symptoms; Cognition Disorders; Family Health; Fem | 1999 |
25 other studies available for risperidone and Genetic Predisposition
| Article | Year |
|---|---|
The influence of
Topics: Antipsychotic Agents; China; Genetic Predisposition to Disease; Humans; Polymorphism, Single Nucleot | 2022 |
UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.
Topics: Age Factors; Autism Spectrum Disorder; Child; Female; Genetic Predisposition to Disease; Glucuronosy | 2018 |
Gabrb2-knockout mice displayed schizophrenia-like and comorbid phenotypes with interneuron-astrocyte-microglia dysregulation.
Topics: Animals; Antipsychotic Agents; Astrocytes; Behavior Rating Scale; Female; Genetic Predisposition to | 2018 |
Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.
Topics: Adolescent; Adult; Antipsychotic Agents; Brazil; Case-Control Studies; Female; Genetic Predispositio | 2018 |
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Amidohydrolases; Antipsychotic Agents; Bo | 2013 |
Association of microRNA137 gene polymorphisms with age at onset and positive symptoms of schizophrenia in a Han Chinese population.
Topics: Adult; Age of Onset; Aripiprazole; China; Female; Genetic Predisposition to Disease; Genotype; Human | 2014 |
Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia.
Topics: Adult; Alleles; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antipsychotic Agents; Female; Genetic | 2014 |
Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Blotting, Western; Disease | 2016 |
Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.
Topics: Adolescent; Alleles; Antipsychotic Agents; Child; Cross-Sectional Studies; Female; Genetic Predispos | 2015 |
Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect.
Topics: Animals; Antipsychotic Agents; Cardiovascular Diseases; Clozapine; Comorbidity; Genetic Predispositi | 2016 |
Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Asian People; China; Demography; Female; Gene Frequency; Genetic Predis | 2008 |
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepine | 2008 |
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Female; Gene Frequency; Genetic P | 2009 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Gene Frequency; Genetic Li | 2011 |
Novel clinical finding in MECP2 duplication syndrome.
Topics: Child; Child Development; Chromosomes, Human, X; Cognitive Behavioral Therapy; Early Intervention, E | 2011 |
Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.
Topics: 5' Flanking Region; Adolescent; Adult; Antipsychotic Agents; Asian People; Case-Control Studies; Chi | 2012 |
Neuroleptics and family history of Parkinson diseases: case report.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Diagnostic Errors; Female; | 2001 |
Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Brain; Brain Chemistry; China; DNA Mutational Analysis; Drug Resistance | 2007 |
Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia.
Topics: Adult; Alleles; Animals; Antipsychotic Agents; Behavior, Animal; Chi-Square Distribution; Disease Mo | 2007 |
Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Female; Gene Frequency; Genetic Predisposition to Disease; Genoty | 2007 |
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Antipsychotic Agents; B | 2009 |
[22q11.2 deletion and schizophrenia in childhood and adolescence].
Topics: Adolescent; Antipsychotic Agents; Calcium; Child; Chromosome Deletion; Chromosomes, Human, Pair 22; | 2007 |
RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Female; Genetic Predisposition to Disease; Genotype; Hu | 2008 |
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Drug Interactions; Genet | 2001 |